A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

Autor: Hunfeld, N.G., Touw, D.J., Mathot, R.A., Mulder, P.G.H., Van Schaik, R.H., Kuipers, E.J., Kooiman, J.C., Geus, W.P.

Publikováno v: Alimentary pharmacology & therapeutics, 31(1), 150-159. Wiley-Blackwell
Alimentary Pharmacology & Therapeutics, 31, 150-159. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics, 31(1), 150-159. Wiley

Background: Esomeprazole and pantoprazole are metabolized in the liver and the polymorphic CYP2C19 enzyme is involved in that process. This genetic polymorphism determines fast (70% of Caucasians), intermediate (25-30% of Caucasians) and slow (2-5% o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad24ec431624bbf350de20bc5803679
https://pure.amc.nl/en/publications/a-comparison-of-the-acidinhibitory-effects-of-esomeprazole-and-pantoprazole-in-relation-to-pharmacokinetics-and-cyp2c19-polymorphism(ec516526-a1cb-452d-a9b3-5994b32e6790).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.